Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study
Léo Plaçais(Inserm), Célèste Lebbé(Inserm), O. Dereure(Beth Israel Deaconess Medical Center), S. Dalac(CHU Dijon Bourgogne), Jean‐Philippe Arnault(Centre Hospitalier Universitaire Amiens-Picardie), Thierry Lesimple, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), F. Granel‐Brocard(Centre Hospitalier Régional et Universitaire de Nancy), Henri Montaudié(Hôpital l'Archet), F. Brunet‐Possenti(Inserm), E. Maubec(Inserm), F. Aubin(Centre Hospitalier Universitaire de Besançon), Délphine Legoupil(Centre Hospitalier Régional Universitaire de Brest), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Jean‐Jacques Grob(Aix-Marseille Université), Clara Allayous(Inserm), Stéphane Dalle(Hospices Civils de Lyon), Laurent Mortier, Pierre‐Emmanuel Stoebner(Centre Hospitalier Universitaire de Nîmes), Julie De Quatrebarbes(Centre Hospitalier Annecy Genevois), Sabiha Trabelsi(Centre Hospitalier Universitaire de Grenoble), Bastien Oriano(Hôtel-Dieu de Paris)
Cited by 34
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k